[Skip to Navigation]
May 10, 2016

Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine

Author Affiliations
  • 1Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California
  • 3Department of Obstetrics and Gynecology, School of Medicine, Virginia Commonwealth University School of Medicine, Richmond
JAMA. 2016;315(18):1943-1944. doi:10.1001/jama.2016.2640

Most women with ovarian cancer present at an advanced stage, when the case-fatality rate is high. Approximately 22 280 women are diagnosed with ovarian cancer in the United States each year; 60% are classified as advanced stage, and the overall 5-year survival for these women is 28%.1 Reliable approaches for early detection of ovarian cancer have thus far been difficult to establish. The recently released report from the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine Committee on the State of the Science in Ovarian Cancer Research, titled Ovarian Cancers: Evolving Paradigms in Research and Care,2 highlights key gaps in the evidence base of ovarian cancer research and underscores opportunities that could affect many women. This congressionally mandated report, sponsored by the Centers for Disease Control and Prevention, has its origins in the Gynecologic Cancer Education and Awareness Act—more commonly known as Johanna’s Law, named for Johanna Silver Gordon, a schoolteacher who died of ovarian cancer.